BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative drugs for the treatment of eye disease, today announced that it will host a Virtual Investor R&D Day from 11am-12:45pm ET on March 30, 2022.
Clinical and scientific opinion leaders in ophthalmology and members of Graybug’s management team will provide general information on eye diseases, such as wet age-related macular degeneration, primary open-angle glaucoma, as well as as its newly acquired assets in inherited corneal and retinal diseases under the company’s pipeline and drug discovery programs. Additionally, Graybug will provide a strategic perspective.
The meeting will include presentations by:
Rahul Bhola, MD, MBA – President and Medical Director of Ophthalmology, Children’s Hospital of Orange County; Head of Division of Pediatric Ophthalmology at CHOC Children’s Specialists; Associate Clinical Professor, University of California, Irvine School of MedicineArshad Khanani, MD, MA – Managing Partner and Director of Clinical Research and Fellowship Director at Sierra Eye Associates; Clinical Associate Professor at the University of Nevada, Reno School of MedicineFrançois Paquet-Durand, PhD – Professor at the Research Institute of Ophthalmology, Tübingen, Germany; Scientific Director of Mireca Medicines GmbHKuldev Singh, MD, MPH – Professor of Ophthalmology and Director of Glaucoma Service at Stanford University School of Medicine
To register, please register here. Additionally, registration for this event and access to the webcast will be available in the Investors and Media section of the Company’s website at https://investors.graybug.vision/news-events/events-presentations, as well as an archived replay after the live event. Participants can also join by dialing (844) 955-2748 (domestic) or (929) 517-0407 (international) and entering conference ID # 9785187.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of eye diseases. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burden and ultimately account, providing better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the panvascular endothelial growth factor (VEGF) inhibitor sunitinib malate targeting a six month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, a proprietary implant formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosage regimen of once every six months. Founded in 2011 based on technology licensed from Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, CA and Baltimore, MD. For more information, please visit www.graybug.vision.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s clinical pipeline, its ability to advance GB-102, GB-401, or any future product candidates in preclinical or clinical development, its ability to achieve planned milestones within the timelines set forth above or at all, its ability to conduct planned operations under the evolving constraints resulting from the COVID-19 pandemic, and the timing, cost and results of its clinical trials. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual operations or results to differ materially from those expressed in any forward-looking statement, including the risks and uncertainties described under “Risk Factors”. in the company’s annual report on Form 10-K filed with the SEC on March 11, 2022 for the fiscal year ended December 31, 2021, in its subsequent quarterly reports on Form 10-Q, and in such other reports as the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Copyright 2022 GlobeNewswire, Inc.
